Group 1 - The article does not provide any specific company or industry analysis, focusing instead on the author's qualifications and disclosures [1][2][3]

Core Insights - Jyong Biotech Ltd. has completed its Nasdaq IPO and participated in the BIO 2025 International Convention, enhancing its visibility in the global biotechnology market [1][2][3] Company Overview - Jyong Biotech is a Taiwan-based biotechnology company focused on developing plant-derived drugs for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][5] - The company has been operational since 2002 and has developed integrated capabilities across drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [5] Product Focus - The flagship product, MCS-2, targets the benign prostatic hyperplasia (BPH) market, which is projected to grow from $4.1 billion in 2020 to $9.8 billion by 2026, driven by global aging and rising obesity rates [2] - MCS-2 aims to provide safe therapeutic solutions in a market traditionally dominated by synthetic drugs [3][4] Strategic Initiatives - The company plans to maximize MCS-2's market penetration through regional licensing partnerships and is exploring opportunities in emerging markets [4] - Jyong Biotech is executing a dual-track approach focusing on global licensing and sales network expansion for MCS-2 while continuing research and development in the urology sector [4] Leadership Perspective - Chairwoman Fu-Feng Kuo emphasized the company's commitment to meeting the urgent demand for safe medications in an aging society and establishing a new standard for plant-based drug innovation globally [5]

As filed with the Securities and Exchange Commission on March 11, 2025 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 10 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | --- ...

As filed with the Securities and Exchange Commission on February 6, 2025 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 9 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | -- ...

As filed with the Securities and Exchange Commission on December 18, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 8 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | - ...

As filed with the Securities and Exchange Commission on November 21, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 7 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | - ...

As filed with the Securities and Exchange Commission on October 31, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 6 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Fang Liu, Esq. VCL Law LLP 1945 Old Gallows Road, Suite 260 Vienna, VA 22182 Tel: 703-919-7285 Approximate date of commencement of proposed sale to the public: as soon as practicable after the effective date of this registration statement. ________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 5 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. As filed with the Securities and Exchange Commission on October 4, 2024 Registration Statement No. 333-277725 If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐ (Exact name o ...

As filed with the Securities and Exchange Commission on September 13, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 4 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | ...

As filed with the Securities and Exchange Commission on August 2, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) Fang Liu, Esq. VCL Law LLP 1945 Old Gallows Road, Suite ...